NASDAQ:ENTX Entera Bio Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Entera Bio Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.32 -0.01 (-0.75 %) (As of 09/22/2020 12:00 AM ET) Add Compare Share Today's Range$1.31Now: $1.32▼$1.3750-Day Range$1.05MA: $1.35▼$1.7552-Week Range$1.00Now: $1.32▼$3.40Volume46,383 shsAverage Volume292,305 shsMarket Capitalization$15.09 millionP/E RatioN/ADividend YieldN/ABeta1.37 ProfileAnalyst RatingsChartCompetitorsEarningsInstitutional OwnershipHeadlinesShort InterestSocial Media Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Entera Bio Ltd. operates as a subsidiary of D.N.A Biomedical Solutions Ltd.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingEntera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Entera Bio has a forecasted upside of 506.1% from its current price of $1.32.Amount of Analyst CoverageEntera Bio has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesEntera Bio has received 158 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEntera Bio has received 163 “underperform” votes. (Add your “underperform” vote.)Community SentimentEntera Bio has received 50.78% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Entera Bio and other stocks. Vote “Outperform” if you believe ENTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ENTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEntera Bio does not currently pay a dividend.Dividend GrowthEntera Bio does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Entera Bio insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Entera Bio is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entera Bio is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntera Bio has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.20 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTX Previous Symbol CUSIPN/A CIKN/A Webwww.enterabio.com Phone972-2532-7151Debt Debt-to-Equity Ratio0.01 Current Ratio2.56 Quick Ratio2.56Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$240,000.00 Price / Sales62.87 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book1.27Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-10,800,000.00 Net MarginsN/A Return on Equity-151.10% Return on Assets-99.01%Miscellaneous Employees19 Outstanding Shares11,430,000Market Cap$15.09 million Next Earnings Date11/19/2020 (Estimated) OptionableNot Optionable $1.32 -0.01 (-0.75 %) (As of 09/22/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ENTX News and Ratings via Email Sign-up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Entera Bio (NASDAQ:ENTX) Frequently Asked Questions How has Entera Bio's stock price been impacted by Coronavirus? Entera Bio's stock was trading at $2.78 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ENTX shares have decreased by 52.5% and is now trading at $1.32. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Entera Bio? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Entera Bio. When is Entera Bio's next earnings date? Entera Bio is scheduled to release its next quarterly earnings announcement on Thursday, November 19th 2020. View our earnings forecast for Entera Bio. How were Entera Bio's earnings last quarter? Entera Bio Ltd (NASDAQ:ENTX) released its earnings results on Thursday, August, 20th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.05. View Entera Bio's earnings history. What price target have analysts set for ENTX? 1 brokerages have issued 1-year target prices for Entera Bio's shares. Their forecasts range from $8.00 to $8.00. On average, they expect Entera Bio's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 506.1% from the stock's current price. View analysts' price targets for Entera Bio. Are investors shorting Entera Bio? Entera Bio saw a decline in short interest in August. As of August 31st, there was short interest totaling 44,400 shares, a decline of 28.2% from the August 15th total of 61,800 shares. Based on an average daily trading volume, of 709,700 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.4% of the shares of the stock are short sold. View Entera Bio's Short Interest. Who are some of Entera Bio's key competitors? Some companies that are related to Entera Bio include Curis (CRIS), Microbot Medical (MBOT), Allena Pharmaceuticals (ALNA), Genetic Technologies (GENE), Organovo (ONVO), Polarityte (PTE), aTyr Pharma (LIFE), BioCardia (BCDA), BioCardia (BCDA), Acorda Therapeutics (ACOR), Pharmacyte Biotech (PMCB), CytRx (CYTR), Brickell Biotech (BBI), Titan Pharmaceuticals (TTNP) and Seneca Biopharma (SNCA). View all competitors. What other stocks do shareholders of Entera Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Canopy Growth (CGC), Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA). Who are Entera Bio's key executives? Entera Bio's management team includes the following people: Dr. Phillip Schwartz Ph.D., CEO & Director (Age 57)Dr. Hillel Galitzer, Chief Operating Officer (Age 41)Dr. Roger J. Garceau, Chief Devel. Advisor & Director (Age 65)Dr. Arthur C. Santora II, Chief Medical Officer When did Entera Bio IPO? (ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager. What is Entera Bio's stock symbol? Entera Bio trades on the NASDAQ under the ticker symbol "ENTX." Who are Entera Bio's major shareholders? Entera Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Phoenix Holdings Ltd. (0.00%) and Wedbush Securities Inc. (0.00%). Which major investors are selling Entera Bio stock? ENTX stock was sold by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd.. Which major investors are buying Entera Bio stock? ENTX stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. How do I buy shares of Entera Bio? Shares of ENTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Entera Bio's stock price today? One share of ENTX stock can currently be purchased for approximately $1.32. How big of a company is Entera Bio? Entera Bio has a market capitalization of $15.09 million and generates $240,000.00 in revenue each year. Entera Bio employs 19 workers across the globe. What is Entera Bio's official website? The official website for Entera Bio is www.enterabio.com. How can I contact Entera Bio? Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The company can be reached via phone at 972-2532-7151 or via email at [email protected] This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
